Xponance Inc. Takes $34,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS)

Xponance Inc. purchased a new position in Arbutus Biopharma Co. (NASDAQ:ABUS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,486 shares of the biopharmaceutical company’s stock, valued at approximately $34,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. E Fund Management Co. Ltd. bought a new position in Arbutus Biopharma in the 4th quarter worth about $34,000. Raymond James Financial Inc. bought a new stake in shares of Arbutus Biopharma during the 4th quarter valued at about $34,000. Cibc World Markets Corp purchased a new position in shares of Arbutus Biopharma during the fourth quarter worth about $45,000. Ballentine Partners LLC bought a new position in shares of Arbutus Biopharma in the fourth quarter worth approximately $102,000. Finally, XTX Topco Ltd raised its stake in Arbutus Biopharma by 76.2% in the third quarter. XTX Topco Ltd now owns 30,013 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 12,975 shares in the last quarter. Hedge funds and other institutional investors own 43.79% of the company’s stock.

Wall Street Analyst Weigh In

ABUS has been the subject of a number of research reports. Chardan Capital reissued a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research note on Friday. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. Finally, StockNews.com upgraded Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Arbutus Biopharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.

Arbutus Biopharma Stock Performance

Shares of ABUS opened at $3.50 on Friday. Arbutus Biopharma Co. has a fifty-two week low of $2.30 and a fifty-two week high of $4.73. The firm has a market cap of $663.22 million, a price-to-earnings ratio of -8.14 and a beta of 1.93. The firm has a 50 day moving average price of $3.34 and a 200-day moving average price of $3.56.

Arbutus Biopharma (NASDAQ:ABUS) last posted its quarterly earnings results on Thursday, March 27th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. The business had revenue of $1.57 million during the quarter, compared to the consensus estimate of $2.20 million. As a group, equities research analysts predict that Arbutus Biopharma Co. will post -0.39 earnings per share for the current year.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.